Clinical Observation of Early Use Ozagrel in the Treatment of Acute Cerebral Infarction

OBJECTIVE: To observe the clinical efficacy of ozagrel on high-sensitivity C-reactive protein (hs-CRP) and interleukin-6(IL-6) in patients with acute cerebral infarction in the early phase. METHODS: 60 patients with acute cerebral infarction were randomly divided into control group and ozagrel group. All patients received the treatment of antihypertension, lowering intracranial hypertension, activator of brain cells and anticoagulation by taking aspirin. And oazgrel group additionally got treatment of continuous intravenous infusion of ozagrel 80 mg, twice a day, for 1 week. The changes of plasma level of hs-CRP and IL-6 were observed before and after treatment, and the neural function deficit evaluation and the record of adverse reaction were all conducted. RESULTS: The levels of hs-CRP, IL-6, and neural function defects score of both groups decreased significantly after 1 week treatment (P0.01 or P0.05), and that of ozagrel group decreased more obviously (P0.05). No obvious adverse drug reaction was observed in ozagrel group. CONCLUSIONS: There is a certain clinic effect of ozagrel in the treatment of acute cerebral infarction in the early phase. It can improve the levels of hs-CRP and IL-6, the hypoxia and ischemia of cerebral infarction area and the neural function deficit with low ADR.